NSG 318 FiNal Exam - PharmacoloGy Exam – (2026/2027) NGN
QuEStioNS aNd caSE ScENarioS (GuaraNtEE PaSS)
SECTION 1: PHARMACOKINETICS & PHARMACODYNAMICS (Questions 1–20)
Question 1
A nurse administers a medication that binds to a receptor and produces a response. This
drug is an:
A) Antagonist
B) Agonist
C) Partial agonist
D) Inverse agonist
corrEct aNSwEr: B) Agonist
Rationale: Agonists bind to receptors and activate them to produce a biological response.
Antagonists (A) bind to receptors but block activation. Partial agonists (C) produce a
submaximal response even when all receptors are occupied. Inverse agonists (D) produce the
opposite effect of an agonist.
Question 2
Which phase of pharmacokinetics involves the movement of a drug from the
bloodstream into tissues?
A) Absorption
B) Distribution
C) Metabolism
D) Excretion
corrEct aNSwEr: B) Distribution
Rationale: Distribution is the process by which drugs are transported from the bloodstream to
tissues and organs. Absorption (A) is movement from the site of administration into the
bloodstream. Metabolism (C) is the chemical alteration of the drug. Excretion (D) is the removal
of the drug from the body.
Question 3
A patient with liver cirrhosis is at risk for drug toxicity due to impaired:
,A) Absorption
B) Distribution
C) Metabolism
D) Excretion
corrEct aNSwEr: C) Metabolism
Rationale: The liver is the primary site of drug metabolism; liver disease can slow metabolism,
leading to drug accumulation and toxicity. Absorption (A) occurs primarily in the GI tract.
Distribution (B) is affected by blood flow and protein binding. Excretion (D) occurs primarily
through the kidneys.
Question 4
Which drug property most increases the risk of drug accumulation in adipose tissue?
A) Low protein binding
B) High water solubility
C) High lipid solubility
D) Large molecular size
corrEct aNSwEr: C) High lipid solubility
Rationale: Highly lipid-soluble (lipophilic) drugs readily cross cell membranes and accumulate
in adipose tissue, leading to a large volume of distribution and prolonged half-life. Water-soluble
drugs (B) remain in the bloodstream and are excreted more rapidly.
Question 5
Which organ is the primary site of drug excretion?
A) Liver
B) Lung
C) Kidney
D) Skin
corrEct aNSwEr: C) Kidney
Rationale: The kidneys excrete most drugs via glomerular filtration and tubular secretion. The
liver (A) is the primary site of metabolism. The lungs (B) and skin (D) play minor roles in
excretion.
Question 6
A patient taking warfarin starts taking rifampin. The INR decreases. This interaction is
due to:
, A) CYP450 enzyme induction
B) CYP450 enzyme inhibition
C) Increased protein binding
D) Reduced absorption
corrEct aNSwEr: A) CYP450 enzyme induction
Rationale: Rifampin induces CYP450 enzymes, increasing warfarin metabolism, reducing its
anticoagulant effect, and lowering the INR. CYP450 inhibition (B) would increase drug levels.
Warfarin is highly protein-bound, but rifampin's primary effect is enzyme induction.
Question 7
A drug that binds to a receptor and produces a maximal response is called a(n):
A) Antagonist
B) Partial agonist
C) Full agonist
D) Inverse agonist
corrEct aNSwEr: C) Full agonist
Rationale: A full agonist binds to a receptor and activates it to produce the maximum possible
response. An antagonist (A) blocks the receptor. A partial agonist (B) produces a submaximal
response. An inverse agonist (D) produces the opposite effect.
Question 8
The process by which a drug moves from the site of administration into the bloodstream
is called:
A) Absorption
B) Distribution
C) Metabolism
D) Excretion
corrEct aNSwEr: A) Absorption
Rationale: Absorption is the first pharmacokinetic phase. Distribution (B) is transport to
tissues; metabolism (C) is biotransformation; excretion (D) is elimination. Bioavailability refers to
the fraction of the administered drug that reaches systemic circulation.
Question 9
A drug with a narrow therapeutic index requires:
QuEStioNS aNd caSE ScENarioS (GuaraNtEE PaSS)
SECTION 1: PHARMACOKINETICS & PHARMACODYNAMICS (Questions 1–20)
Question 1
A nurse administers a medication that binds to a receptor and produces a response. This
drug is an:
A) Antagonist
B) Agonist
C) Partial agonist
D) Inverse agonist
corrEct aNSwEr: B) Agonist
Rationale: Agonists bind to receptors and activate them to produce a biological response.
Antagonists (A) bind to receptors but block activation. Partial agonists (C) produce a
submaximal response even when all receptors are occupied. Inverse agonists (D) produce the
opposite effect of an agonist.
Question 2
Which phase of pharmacokinetics involves the movement of a drug from the
bloodstream into tissues?
A) Absorption
B) Distribution
C) Metabolism
D) Excretion
corrEct aNSwEr: B) Distribution
Rationale: Distribution is the process by which drugs are transported from the bloodstream to
tissues and organs. Absorption (A) is movement from the site of administration into the
bloodstream. Metabolism (C) is the chemical alteration of the drug. Excretion (D) is the removal
of the drug from the body.
Question 3
A patient with liver cirrhosis is at risk for drug toxicity due to impaired:
,A) Absorption
B) Distribution
C) Metabolism
D) Excretion
corrEct aNSwEr: C) Metabolism
Rationale: The liver is the primary site of drug metabolism; liver disease can slow metabolism,
leading to drug accumulation and toxicity. Absorption (A) occurs primarily in the GI tract.
Distribution (B) is affected by blood flow and protein binding. Excretion (D) occurs primarily
through the kidneys.
Question 4
Which drug property most increases the risk of drug accumulation in adipose tissue?
A) Low protein binding
B) High water solubility
C) High lipid solubility
D) Large molecular size
corrEct aNSwEr: C) High lipid solubility
Rationale: Highly lipid-soluble (lipophilic) drugs readily cross cell membranes and accumulate
in adipose tissue, leading to a large volume of distribution and prolonged half-life. Water-soluble
drugs (B) remain in the bloodstream and are excreted more rapidly.
Question 5
Which organ is the primary site of drug excretion?
A) Liver
B) Lung
C) Kidney
D) Skin
corrEct aNSwEr: C) Kidney
Rationale: The kidneys excrete most drugs via glomerular filtration and tubular secretion. The
liver (A) is the primary site of metabolism. The lungs (B) and skin (D) play minor roles in
excretion.
Question 6
A patient taking warfarin starts taking rifampin. The INR decreases. This interaction is
due to:
, A) CYP450 enzyme induction
B) CYP450 enzyme inhibition
C) Increased protein binding
D) Reduced absorption
corrEct aNSwEr: A) CYP450 enzyme induction
Rationale: Rifampin induces CYP450 enzymes, increasing warfarin metabolism, reducing its
anticoagulant effect, and lowering the INR. CYP450 inhibition (B) would increase drug levels.
Warfarin is highly protein-bound, but rifampin's primary effect is enzyme induction.
Question 7
A drug that binds to a receptor and produces a maximal response is called a(n):
A) Antagonist
B) Partial agonist
C) Full agonist
D) Inverse agonist
corrEct aNSwEr: C) Full agonist
Rationale: A full agonist binds to a receptor and activates it to produce the maximum possible
response. An antagonist (A) blocks the receptor. A partial agonist (B) produces a submaximal
response. An inverse agonist (D) produces the opposite effect.
Question 8
The process by which a drug moves from the site of administration into the bloodstream
is called:
A) Absorption
B) Distribution
C) Metabolism
D) Excretion
corrEct aNSwEr: A) Absorption
Rationale: Absorption is the first pharmacokinetic phase. Distribution (B) is transport to
tissues; metabolism (C) is biotransformation; excretion (D) is elimination. Bioavailability refers to
the fraction of the administered drug that reaches systemic circulation.
Question 9
A drug with a narrow therapeutic index requires:
